Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
Firstsource Solutions among 5 stocks close crossing below VWAPFive Nifty500 stocks fell over two percent below VWAP, signaling bearish sentiment and increased selling pressure, as closing prices droppe...
Negative Breakout: These 11 stocks cross below their 200 DMAsThe 200 DMA is used as a key indicator by traders for determining the overall trend in a particular stock.
Stocks in news: Infosys, Trent, Jio Financial, Hindustan Copper, Adani EnergyMarkets experienced a corrective session, with Nifty expected to consolidate but maintain a positive bias. Key stocks like Infosys, Trent, ...
Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
Alkem Laboratories launches semaglutide in India at Rs 450 per week, eyes booming weight-loss marketAlkem Laboratories has launched a new semaglutide injection in India. This drug targets the growing diabetes and weight loss market. It is ...
Obesity bet may drive focus on chronic segment: Alkem LabsAlkem Labs anticipates its upcoming semaglutide launch will drive a strategic shift from acute treatments to chronic care, including diabet...
Add Alkem Laboratories, target price Rs 5,700: HDFC SecuritiesHDFC Securities suggests adding Alkem Laboratories shares, targeting Rs 5,700. Alkem, a large pharmaceutical company, reported its financia...
Add Alkem Laboratories, target price Rs 6,180: HDFC SecuritiesHDFC Securities recommends buying shares of Alkem Laboratories. They set a target price of Rs 6,180. The current market price is Rs 5,535. ...
Add Alkem Laboratories, target price Rs 5520: HDFC SecuritiesAlkem Laboratories Ltd., incorporated in the year 1973, is a Large Cap company (having a market cap of Rs 60260.76 Crore) operating in Phar...
Alkem Labs plunges more than 13%, sees biggest single-day fall in over 3 years on tax evasion allegationIn September last year, the tax department conducted surveys on the offices and premises of the company after receiving intelligence regard...
Buy Alkem Laboratories, target Rs 2,340: HDFC SecuritiesBuy Alkem Laboratories at a price target of Rs 2,340.
Alkem's Mandva plant gets establishment nod from USFDAAlkem Labs Ltd today said one of its manufacturing plants in Gujarat has obtained the Establishment Inspection Report (EIR) "approval" from...